Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Stem Cells (Dayton, Ohio)|March 22, 2008
Selection against undifferentiated human embryonic stem cells by a cytotoxic antibody recognizing podocalyxin-like protein-1Andre B Choo, Heng Liang Tan, Sheu Ngo Ang, et al.
Cancer Medicine|January 10, 2014
Early detection of antiangiogenic treatment responses in a mouse xenograft tumor model using quantitative perfusion MRIReshmi Rajendran, Wei Huang, Annie Mei Yee Tang, et al.
Molecular Cancer Therapeutics|May 19, 2011
Pharmacodynamic evaluation of the target efficacy of SB939, an oral HDAC inhibitor with selectivity for tumor tissueVeronica Novotny-Diermayr, Nina Sausgruber, Yung Kiang Loh, et al.
Plos One|May 9, 2019
The chromatin structuring protein HMGA2 influences human subtelomere stability and cancer chemosensitivitySyed Moiz Ahmed, Priya Dharshana Ramani, Stephen Qi Rong Wong, et al.
Frontiers in Bioengineering and Biotechnology|September 23, 2022
A comparative study of tumour-on-chip models with patient-derived xenografts for predicting chemotherapy efficacy in colorectal cancer patientsLouis Jun Ye Ong, Shumei Chia, Stephen Qi Rong Wong, et al.
Stem Cells and Development|September 6, 2007
Directed differentiation of human embryonic stem cells into the pancreatic endocrine lineageBlaine W Phillips, Hannes Hentze, William L Rust, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 28, 2015
Evaluation of cynomolgus monkeys for the identification of endogenous biomarkers for hepatic transporter inhibition and as a translatable model to predict pharmacokinetic interactions with statins in humansXiaoyan Chu, Shian-Jiun Shih, Rachel Shaw, et al.
Molecular Cancer Therapeutics|March 4, 2010
SB939, a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancerVeronica Novotny-Diermayr, Kanda Sangthongpitag, Chang Yong Hu, et al.
Infectious Diseases and Therapy|September 4, 2022
First-in-Human Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Rapidly Developed SARS-CoV-2 Therapeutic Antibody, AOD01, in Healthy AdultsVenkateshan S Prativadibhayankaram, Lawrence Soon-U Lee, David Lye, et al.
Nature Communications|September 7, 2017
Phenotype-driven precision oncology as a guide for clinical decisions one patient at a timeShumei Chia, Joo-Leng Low, Xiaoqian Zhang, et al.
Pageof 3